- Home
- USA vs IBRX Comparison
USA vs IBRX Comparison
Compare USA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USA
- IBRX
- Stock Information
- Founded
- USA 1986
- IBRX 2014
- Country
- USA United States
- IBRX United States
- Employees
- USA N/A
- IBRX N/A
- Industry
- USA Finance Companies
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USA Finance
- IBRX Health Care
- Exchange
- USA Nasdaq
- IBRX Nasdaq
- Market Cap
- USA 1.9B
- IBRX 2.3B
- IPO Year
- USA N/A
- IBRX N/A
- Fundamental
- Price
- USA $6.49
- IBRX $2.76
- Analyst Decision
- USA
- IBRX Strong Buy
- Analyst Count
- USA 0
- IBRX 6
- Target Price
- USA N/A
- IBRX $9.83
- AVG Volume (30 Days)
- USA 880.5K
- IBRX 9.7M
- Earning Date
- USA 01-01-0001
- IBRX 11-11-2025
- Dividend Yield
- USA 9.66%
- IBRX N/A
- EPS Growth
- USA N/A
- IBRX N/A
- EPS
- USA N/A
- IBRX N/A
- Revenue
- USA N/A
- IBRX $56,600,000.00
- Revenue This Year
- USA N/A
- IBRX $629.94
- Revenue Next Year
- USA N/A
- IBRX $109.91
- P/E Ratio
- USA N/A
- IBRX N/A
- Revenue Growth
- USA N/A
- IBRX 4227.22
- 52 Week Low
- USA $5.62
- IBRX $1.83
- 52 Week High
- USA $7.09
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- USA 41.22
- IBRX 64.62
- Support Level
- USA $6.46
- IBRX $2.32
- Resistance Level
- USA $6.60
- IBRX $2.67
- Average True Range (ATR)
- USA 0.07
- IBRX 0.14
- MACD
- USA -0.01
- IBRX 0.05
- Stochastic Oscillator
- USA 16.67
- IBRX 72.73
About USA Liberty All-Star Equity Fund
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.